Gain Therapeutics’ (GANX) Buy Rating Reiterated at HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $8.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 236.13% from the company’s current price.

GANX has been the topic of a number of other reports. Roth Mkm reiterated a “buy” rating and issued a $7.00 target price on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Scotiabank began coverage on Gain Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 target price on the stock. Finally, Roth Capital upgraded Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Price Performance

NASDAQ:GANX opened at $2.38 on Monday. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The business’s 50-day simple moving average is $2.23 and its two-hundred day simple moving average is $2.01. The stock has a market cap of $63.13 million, a PE ratio of -2.16 and a beta of 0.14. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $4.63.

Institutional Investors Weigh In On Gain Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sprott Inc. purchased a new stake in Gain Therapeutics during the fourth quarter valued at approximately $30,000. Benedict Financial Advisors Inc. purchased a new stake in Gain Therapeutics during the fourth quarter valued at approximately $35,000. Bridgeway Capital Management LLC purchased a new stake in Gain Therapeutics during the fourth quarter valued at approximately $65,000. Northern Trust Corp raised its position in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after purchasing an additional 39,642 shares during the period. Finally, Jones Financial Companies Lllp raised its position in Gain Therapeutics by 83.6% during the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after purchasing an additional 44,750 shares during the period. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.